Australian experts have issued a blunt warning about artificial intelligence tools marketed for skin cancer checks, according to a report from The Courier Mail. The headline verdict is short and unambiguous: do not rely on AI alone to decide whether a mole, spot or lesion is dangerous.

That's a strong claim, and it lands in a market where AI-assisted skin checks are no longer hypothetical. Smartphone apps and clinic-based algorithms now sit between patients and dermatologists more often than most clinicians would have predicted even a few years ago. The expert position reported here pulls that trend up short.

What exactly are the experts warning about?

According to The Courier Mail's report, the warning targets the gap between what AI skin-check tools promise and what they can reliably deliver. The concern is straightforward: a consumer-facing algorithm that clears a lesion can give a patient false reassurance, and false reassurance in melanoma is not a neutral outcome — it's delayed diagnosis, delayed excision and, potentially, a worse stage at presentation.

The report frames the expert message as deliberately blunt. Rather than hedging with the usual language about AI as an "adjunct" or "decision-support" tool, the specialists quoted are drawing a hard line on where the technology's authority ends.

Dermatologists have raised this caution before in journals and at congresses, but a blunt public warning through mainstream press signals a shift in tone — from academic debate to consumer-facing advice. That matters for uptake. Patients who read a nuanced position paper rarely change behavior; patients who read a newspaper warning titled as this one is might.

Why does this matter for melanoma detection?

Melanoma outcomes are driven by one variable more than any other: time. Lesions caught early, while thin, carry a dramatically better prognosis than lesions caught late, once they have thickened or spread. Staging language — Breslow thickness, ulceration status, AJCC stage — exists precisely because millimeters at excision change survival conversations.

Any tool that delays a patient's first dermatology visit works against that clock. A false "benign" result from an app can cost weeks or months. The experts' warning, as reported, is essentially a reminder of that arithmetic: no algorithm output is worth the delay it may introduce if it persuades a patient to skip the consultation.

The obverse failure mode also exists. An app that flags everything as suspicious doesn't protect patients either — it floods clinics with low-risk referrals, erodes trust in the technology, and can produce anxiety-driven over-checking without improving detection of the lesions that actually matter.

What does this change for patients and practices?

For patients, the practical takeaway from the reported warning is simple: a phone app is not a skin check. Any lesion that is new, changing, bleeding, itching or otherwise worrying warrants an in-person assessment, regardless of what an algorithm says. The expert position, as The Courier Mail reports it, treats AI output as information a clinician might weigh — not as a verdict a patient should act on.

For dermatology practices, the warning cuts two ways. It reinforces the clinical primacy of the dermatologist's examination — dermoscopy, history-taking, excision decisions — over automated triage. But it also doesn't make AI disappear. Clinics will keep fielding questions from patients who have already run an app before booking, and front-desk and triage protocols increasingly need an answer ready: "what did the app say" is becoming part of the intake conversation whether practices plan for it or not.

The report does not claim the technology has no future. The experts' objection, as summarized, is to AI operating outside clinical oversight — patients self-triaging lesions against algorithmic output with no dermatologist in the loop.

The bottom line

The Courier Mail report captures a moment where dermatology's professional voice has chosen clarity over diplomacy: AI skin cancer checks, in their current consumer-facing form, are not a substitute for a dermatologist's eyes. The open question — and the one both device developers and regulators will have to answer — is whether these tools can be repositioned as clinician-supervised aids fast enough to keep public trust in dermatologic AI intact.